Evaluation of Virtual Reality Headsets on Cancer Patients During Day Hospital Stay
Not Applicable
Completed
- Conditions
- Cancer
- Registration Number
- NCT06814912
- Lead Sponsor
- Institut Sainte Catherine
- Brief Summary
Use of virtula reality headsets during treatment course on day hospitalized cancer patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- cancer patients
- chemotherapy treatment
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Rate of patients with nausea reduction compared with preview treatment administration From the first chemotherapy injection until the end of chemotherapy injection with the virtual reality headset (at the end of the third cycle; each cycle is 21 days) ) survey : improvement of nausea
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does virtual reality headset use impact neuroplasticity markers in hospitalized cancer patients?
What is the comparative effectiveness of VR vs standard-of-care analgesics for pain management in oncology day care?
Which biomarkers predict response to virtual reality interventions in metastatic breast cancer patients during treatment?
What adverse events are associated with prolonged VR headset use in immunocompromised cancer patients?
How does VR therapy compare to music therapy in reducing cortisol levels among hematologic malignancy patients?
Trial Locations
- Locations (1)
ICAP
🇫🇷Avignon, France